LT3013861T - Anti-fcrh5 antikūnai - Google Patents
Anti-fcrh5 antikūnaiInfo
- Publication number
- LT3013861T LT3013861T LTEP14742047.5T LT14742047T LT3013861T LT 3013861 T LT3013861 T LT 3013861T LT 14742047 T LT14742047 T LT 14742047T LT 3013861 T LT3013861 T LT 3013861T
- Authority
- LT
- Lithuania
- Prior art keywords
- fcrh5 antibodies
- fcrh5
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361838534P | 2013-06-24 | 2013-06-24 | |
PCT/US2014/043952 WO2014210064A1 (en) | 2013-06-24 | 2014-06-24 | Anti-fcrh5 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3013861T true LT3013861T (lt) | 2018-02-12 |
Family
ID=51212984
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP17198415.6T LT3336106T (lt) | 2013-06-24 | 2014-06-24 | Anti-fcrh5 antikūnai |
LTEP14742047.5T LT3013861T (lt) | 2013-06-24 | 2014-06-24 | Anti-fcrh5 antikūnai |
LTEP20169942.8T LT3736291T (lt) | 2013-06-24 | 2014-06-24 | Anti-fcrh5 antikūnai |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP17198415.6T LT3336106T (lt) | 2013-06-24 | 2014-06-24 | Anti-fcrh5 antikūnai |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP20169942.8T LT3736291T (lt) | 2013-06-24 | 2014-06-24 | Anti-fcrh5 antikūnai |
Country Status (29)
Country | Link |
---|---|
US (3) | US10435471B2 (lt) |
EP (3) | EP3336106B1 (lt) |
JP (2) | JP6684208B2 (lt) |
KR (1) | KR20160022912A (lt) |
CN (2) | CN116063515A (lt) |
AR (1) | AR096687A1 (lt) |
AU (2) | AU2014302617B2 (lt) |
BR (1) | BR112015032224B1 (lt) |
CA (1) | CA2915480C (lt) |
DK (3) | DK3736291T5 (lt) |
ES (3) | ES2962874T3 (lt) |
FI (1) | FI3736291T3 (lt) |
HK (3) | HK1222663A1 (lt) |
HR (3) | HRP20231323T1 (lt) |
HU (3) | HUE063910T2 (lt) |
IL (2) | IL243129B (lt) |
LT (3) | LT3336106T (lt) |
MX (1) | MX2015017331A (lt) |
MY (2) | MY176285A (lt) |
NO (1) | NO2955475T3 (lt) |
PL (3) | PL3013861T3 (lt) |
PT (3) | PT3736291T (lt) |
RS (3) | RS56878B1 (lt) |
RU (2) | RU2687132C2 (lt) |
SG (2) | SG11201510653YA (lt) |
SI (3) | SI3336106T1 (lt) |
TW (1) | TWI725931B (lt) |
WO (1) | WO2014210064A1 (lt) |
ZA (2) | ZA201509261B (lt) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR096687A1 (es) | 2013-06-24 | 2016-01-27 | Genentech Inc | Anticuerpos anti-fcrh5 |
NZ721309A (en) | 2013-12-17 | 2019-11-29 | Genentech Inc | Anti-cd3 antibodies and methods of use |
US10973920B2 (en) | 2014-06-30 | 2021-04-13 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
CA2954414A1 (en) | 2014-07-15 | 2016-01-21 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
BR112017004802A2 (pt) | 2014-09-12 | 2017-12-12 | Genentech Inc | anticorpos anti-cll-1 e imunoconjugados |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
WO2016090337A1 (en) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
EP3259285A2 (en) | 2015-02-16 | 2017-12-27 | Lonza Ltd | Cl and/or ch1 mutated antibodies for drug conjugation |
ES2957567T3 (es) * | 2015-06-16 | 2024-01-22 | Hoffmann La Roche | Anticuerpos humanizados y de afinidad madurada contra FcRH5 y procedimientos de uso |
JP6996983B2 (ja) | 2015-06-16 | 2022-02-21 | ジェネンテック, インコーポレイテッド | 抗cll-1抗体及び使用方法 |
MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
BR112018011336A2 (pt) * | 2015-12-04 | 2018-12-04 | Memorial Sloan-Kettering Cancer Center | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer |
KR20190074300A (ko) | 2016-11-15 | 2019-06-27 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약 |
BR112019011186A2 (pt) | 2016-12-01 | 2019-10-08 | Regeneron Pharma | conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor. |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CN118557758A (zh) | 2017-02-10 | 2024-08-30 | 瑞泽恩制药公司 | 用于免疫-pet成像的放射性标记的抗-lag3抗体 |
EP3658193A1 (en) | 2017-07-24 | 2020-06-03 | Regeneron Pharmaceuticals, Inc. | Anti-cd8 antibodies and uses thereof |
BR112020008565A2 (pt) | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | processo para a produção de uma composição de célula t |
US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
BR112020008323A2 (pt) | 2017-11-01 | 2020-11-03 | Juno Therapeutics Inc | anticorpos e receptores de antígenos quiméricos específicos para antígeno de maturação de células b |
US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
KR20200099132A (ko) | 2017-11-01 | 2020-08-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 조작된 세포의 치료적 조성물을 생성하기 위한 프로세스 |
US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
TW201925782A (zh) | 2017-11-30 | 2019-07-01 | 瑞士商諾華公司 | 靶向bcma之嵌合抗原受體及其用途 |
BR112020011144A2 (pt) | 2017-12-08 | 2020-11-17 | Juno Therapeutics Inc | formulação de meio livre de soro para o cultivo de células e métodos de uso da mesma |
BR112020011223A2 (pt) | 2017-12-08 | 2020-11-17 | Juno Therapeutics Inc | marcadores fenotípicos para terapia celular e mé-todos relacionados |
KR20200108278A (ko) | 2017-12-08 | 2020-09-17 | 주노 쎄러퓨티크스 인코퍼레이티드 | 조작된 t 세포의 조성물을 제조하는 방법 |
AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
AU2019277029C1 (en) | 2018-06-01 | 2024-01-04 | Novartis Ag | Binding molecules against BCMA and uses thereof |
US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
BR112021002245A2 (pt) | 2018-08-09 | 2021-05-04 | Juno Therapeutics Inc | métodos para avaliar ácidos nucleicos integrados |
WO2020092854A2 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
CN113329792B (zh) | 2019-02-15 | 2024-06-28 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN114007640A (zh) | 2019-05-01 | 2022-02-01 | 朱诺治疗学股份有限公司 | 从修饰的cd247基因座表达嵌合受体的细胞、相关多核苷酸和方法 |
BR112021021075A2 (pt) | 2019-05-01 | 2021-12-14 | Editas Medicine Inc | Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos |
CA3165274A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
IL297147A (en) | 2020-04-10 | 2022-12-01 | Juno Therapeutics Inc | Methods and Uses Related to Transgenic Cell Therapy with a Chimeric Antigen Receptor Directed to a B-Cell Maturation Antigen |
WO2021231657A1 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
JP2023531531A (ja) | 2020-06-26 | 2023-07-24 | ジュノ セラピューティクス ゲーエムベーハー | 組換え受容体を条件付きで発現する操作されたt細胞、関連ポリヌクレオチド、および方法 |
EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2022098787A1 (en) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
IL302569A (en) | 2020-11-06 | 2023-07-01 | Novartis Ag | CD19 binding molecules and their uses |
WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
MX2023007644A (es) | 2020-12-23 | 2023-07-07 | Sotio Biotech A S | Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2. |
JP2024509853A (ja) | 2021-03-03 | 2024-03-05 | ジュノー セラピューティクス インコーポレイテッド | T細胞療法およびdgk阻害剤の組合せ |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
AU2022267891A1 (en) | 2021-04-27 | 2023-11-09 | Novartis Ag | Viral vector production system |
EP4334341A2 (en) | 2021-05-06 | 2024-03-13 | Juno Therapeutics GmbH | Methods for stimulating and transducing t cells |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
WO2023159182A1 (en) | 2022-02-18 | 2023-08-24 | Rakuten Medical, Inc. | Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use |
TW202408562A (zh) | 2022-04-13 | 2024-03-01 | 美商建南德克公司 | 治療性蛋白質之醫藥組成物及使用方法 |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
CN117384299B (zh) * | 2022-11-01 | 2024-04-30 | 邦恩泰(山东)生物医药科技集团股份有限公司 | 靶向bcma和/或fcrh5的嵌合抗原受体、car-t细胞及其应用 |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
WO2024124132A1 (en) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Machine learning methods for predicting cell phenotype using holographic imaging |
WO2024161021A1 (en) | 2023-02-03 | 2024-08-08 | Juno Therapeutics Gmbh | Methods for non-viral manufacturing of engineered immune cells |
CN116789849B (zh) * | 2023-04-12 | 2024-03-08 | 南京紫珑生物科技有限公司 | 一种嵌合抗原受体及其应用 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
ES2233928T3 (es) | 1993-10-01 | 2005-06-16 | Teikoku Hormone Mfg. Co., Ltd. | Derivados de dolastatina. |
US20020132253A1 (en) | 1997-06-16 | 2002-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
ES2586850T3 (es) | 1999-11-29 | 2016-10-19 | The Trustees Of Columbia University In The City Of New York | Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma |
US7105149B1 (en) | 1999-11-29 | 2006-09-12 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma |
US20040005561A1 (en) | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
CU23007A1 (es) | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
WO2002102973A2 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
MXPA04002593A (es) | 2001-09-18 | 2004-05-31 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumor. |
US7888478B2 (en) | 2002-09-11 | 2011-02-15 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US20050226869A1 (en) | 2001-10-19 | 2005-10-13 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US7858330B2 (en) | 2001-10-19 | 2010-12-28 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
WO2003043583A2 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
ES2579836T3 (es) | 2003-11-06 | 2016-08-17 | Seattle Genetics, Inc. | Compuestos de monometilvalina capaces de conjugación con ligandos |
AU2004308972C1 (en) | 2003-12-24 | 2009-11-26 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
EP1718667B1 (en) * | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
US7999077B2 (en) * | 2004-09-30 | 2011-08-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | IRTA2 antibodies and methods of use |
US20070134243A1 (en) | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
EP1846449A4 (en) | 2005-01-12 | 2009-07-08 | Medarex Inc | IRTA-2 ANTIBODIES AND THEIR USE |
KR100970824B1 (ko) | 2005-06-20 | 2010-07-16 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 조성물 및 방법 |
WO2008109533A2 (en) | 2007-03-02 | 2008-09-12 | Medarex, Inc. | Human antibodies that bind multiple irta family proteins, and uses thereof |
WO2009099741A1 (en) * | 2008-02-01 | 2009-08-13 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
TWI461428B (zh) * | 2008-07-15 | 2014-11-21 | Genentech Inc | 蔥環黴素衍生結合物,其製備方法及作為抗腫瘤化合物之用途 |
US8362213B2 (en) * | 2009-04-01 | 2013-01-29 | Genentech, Inc. | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
CA2757382A1 (en) | 2009-04-01 | 2010-10-21 | Kristi Elkins | Anti-fcrh5 antibodies and immunoconjugates |
CA2772929A1 (en) | 2009-09-03 | 2011-03-11 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
PT2528625E (pt) * | 2010-04-15 | 2013-10-17 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
AR096687A1 (es) | 2013-06-24 | 2016-01-27 | Genentech Inc | Anticuerpos anti-fcrh5 |
NZ721309A (en) | 2013-12-17 | 2019-11-29 | Genentech Inc | Anti-cd3 antibodies and methods of use |
ES2957567T3 (es) | 2015-06-16 | 2024-01-22 | Hoffmann La Roche | Anticuerpos humanizados y de afinidad madurada contra FcRH5 y procedimientos de uso |
-
2014
- 2014-06-23 AR ARP140102352A patent/AR096687A1/es unknown
- 2014-06-23 TW TW103121621A patent/TWI725931B/zh active
- 2014-06-24 CA CA2915480A patent/CA2915480C/en active Active
- 2014-06-24 FI FIEP20169942.8T patent/FI3736291T3/fi active
- 2014-06-24 PL PL14742047T patent/PL3013861T3/pl unknown
- 2014-06-24 PT PT201699428T patent/PT3736291T/pt unknown
- 2014-06-24 US US14/313,822 patent/US10435471B2/en active Active
- 2014-06-24 BR BR112015032224-7A patent/BR112015032224B1/pt active IP Right Grant
- 2014-06-24 ES ES20169942T patent/ES2962874T3/es active Active
- 2014-06-24 DK DK20169942.8T patent/DK3736291T5/da active
- 2014-06-24 PL PL17198415T patent/PL3336106T3/pl unknown
- 2014-06-24 ES ES17198415T patent/ES2812243T3/es active Active
- 2014-06-24 DK DK14742047.5T patent/DK3013861T3/da active
- 2014-06-24 LT LTEP17198415.6T patent/LT3336106T/lt unknown
- 2014-06-24 HU HUE20169942A patent/HUE063910T2/hu unknown
- 2014-06-24 AU AU2014302617A patent/AU2014302617B2/en active Active
- 2014-06-24 JP JP2016521907A patent/JP6684208B2/ja active Active
- 2014-06-24 CN CN202211286136.4A patent/CN116063515A/zh active Pending
- 2014-06-24 KR KR1020167001897A patent/KR20160022912A/ko not_active Application Discontinuation
- 2014-06-24 WO PCT/US2014/043952 patent/WO2014210064A1/en active Application Filing
- 2014-06-24 EP EP17198415.6A patent/EP3336106B1/en active Active
- 2014-06-24 PL PL20169942.8T patent/PL3736291T3/pl unknown
- 2014-06-24 RS RS20180149A patent/RS56878B1/sr unknown
- 2014-06-24 CN CN201480045475.0A patent/CN105473618A/zh active Pending
- 2014-06-24 EP EP20169942.8A patent/EP3736291B1/en active Active
- 2014-06-24 PT PT147420475T patent/PT3013861T/pt unknown
- 2014-06-24 HU HUE17198415A patent/HUE049446T2/hu unknown
- 2014-06-24 SI SI201431623T patent/SI3336106T1/sl unknown
- 2014-06-24 ES ES14742047.5T patent/ES2659229T3/es active Active
- 2014-06-24 HU HUE14742047A patent/HUE036581T2/hu unknown
- 2014-06-24 RU RU2016101965A patent/RU2687132C2/ru active
- 2014-06-24 RS RS20200733A patent/RS60418B1/sr unknown
- 2014-06-24 RU RU2019109452A patent/RU2019109452A/ru unknown
- 2014-06-24 SG SG11201510653YA patent/SG11201510653YA/en unknown
- 2014-06-24 MY MYPI2015704672A patent/MY176285A/en unknown
- 2014-06-24 SI SI201432050T patent/SI3736291T1/sl unknown
- 2014-06-24 MX MX2015017331A patent/MX2015017331A/es active IP Right Grant
- 2014-06-24 EP EP14742047.5A patent/EP3013861B1/en active Active
- 2014-06-24 SI SI201430602T patent/SI3013861T1/en unknown
- 2014-06-24 PT PT171984156T patent/PT3336106T/pt unknown
- 2014-06-24 HR HRP20231323TT patent/HRP20231323T1/hr unknown
- 2014-06-24 SG SG10201804338PA patent/SG10201804338PA/en unknown
- 2014-06-24 RS RS20230745A patent/RS64514B1/sr unknown
- 2014-06-24 DK DK17198415.6T patent/DK3336106T3/da active
- 2014-06-24 LT LTEP14742047.5T patent/LT3013861T/lt unknown
- 2014-06-24 LT LTEP20169942.8T patent/LT3736291T/lt unknown
-
2015
- 2015-05-08 NO NO15001398A patent/NO2955475T3/no unknown
- 2015-12-15 IL IL243129A patent/IL243129B/en active IP Right Grant
- 2015-12-18 ZA ZA2015/09261A patent/ZA201509261B/en unknown
-
2016
- 2016-09-13 HK HK16110816.3A patent/HK1222663A1/zh unknown
- 2016-11-04 HK HK16112724.0A patent/HK1224313A1/zh unknown
-
2018
- 2018-02-27 HR HRP20180352TT patent/HRP20180352T1/hr unknown
- 2018-12-14 ZA ZA2018/08451A patent/ZA201808451B/en unknown
- 2018-12-20 HK HK18116334.1A patent/HK1257261A1/zh unknown
-
2019
- 2019-01-31 MY MYPI2019000547A patent/MY191169A/en unknown
- 2019-09-23 IL IL26952819A patent/IL269528A/en unknown
- 2019-09-26 US US16/583,584 patent/US11352431B2/en active Active
- 2019-10-23 JP JP2019192491A patent/JP2020048559A/ja active Pending
-
2020
- 2020-03-17 AU AU2020201918A patent/AU2020201918A1/en not_active Abandoned
- 2020-07-15 HR HRP20201111TT patent/HRP20201111T1/hr unknown
-
2022
- 2022-05-02 US US17/734,239 patent/US20230096941A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269528A (en) | Anti- FCRH5 antibodies | |
HRP20190502T1 (hr) | Afukozilirana anti-fgfr2iiib protutijela | |
HK1217023A1 (zh) | 新型抗體 | |
GB201322583D0 (en) | Antibodies | |
EP3083682C0 (en) | DOUBLE SPECIFICITY ANTIBODIES | |
HK1220142A1 (zh) | 抗體 | |
GB201308658D0 (en) | Antibodies | |
GB201315486D0 (en) | Antibodies | |
GB201300706D0 (en) | Antibody | |
IL245488B (en) | Anti- ccl17 antibodies | |
GB201312226D0 (en) | Improved antibodies | |
HK1220763A1 (zh) | 免疫試驗 | |
GB201318283D0 (en) | Antibodies |